Cited by 113

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer

Blackford, Amanda, Parmigiani, Giovanni, Kensler, Thomas W., Wolfgang, Christopher, Jones, Siân, Zhang, Xiaosong, Parsons, D. Willams, Lin, Jimmy Cheng-Ho, Leary, Rebecca J., Eshleman, James R., Goggins, Michael, Jaffee, Elizabeth M., Iacobuzio-Donahue, Christine A., Maitra, Anirban, Klein, Alison, Cameron, John L., Olino, Kelly, Schulick, Richard, Winter, Jordan, Vogelstein, Bert, Velculescu, Victor E., Kinzler, Kenneth W., Hruban, Ralph H.·2009·Cancer Research

Abstract

Cigarette smoking doubles the risk of pancreatic cancer, and smoking accounts for 20% to 25% of pancreatic cancers. The recent sequencing of the pancreatic cancer genome provides an unprecedented opportunity to identify mutational patterns associated with smoking. We previously sequenced >750 million bp DNA from 23,219 transcripts in 24 adenocarcinomas of the pancreas (discovery screen). In this previous study, the 39 genes that were mutated more than once in the discovery screen were sequenced in an additional 90 adenocarcinomas of the pancreas (validation screen). Here, we compared the somatic mutations in the cancers obtained from individuals who ever smoked cigarettes (n = 64) to the somatic mutations in the cancers obtained from individuals who never smoked cigarettes (n = 50). When adjusted for age and gender, analyses of the discovery screen revealed significantly more nonsynonymous mutations in the carcinomas obtained from ever smokers (mean, 53.1 mutations per tumor; SD, 27.9) than in the carcinomas obtained from never smokers (mean, 38.5; SD, 11.1; P = 0.04). The difference between smokers and nonsmokers was not driven by mutations in known driver genes in pancreatic cancer (KRAS, TP53, CDKN2A/p16, and SMAD4), but instead was predominantly observed in genes mutated at lower frequency. No differences were observed in mutations in carcinomas from the head versus tail of the gland. Pancreatic carcinomas from cigarette smokers harbor more mutations than do carcinomas from never smokers. The types and patterns of these mutations provide insight into the mechanisms by which cigarette smoking causes pancreatic cancer. [Cancer Res 2009;69(8):3681–8]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-0015

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 45

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96. · DOI
  2. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286: 921–9. · DOI
  3. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830–7. · DOI
  4. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol 1996; 23: 241–50.
  5. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11: 915–23.
  6. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 2008; 393: 535–45. · DOI
  7. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007; 102: 2696–707. · DOI
  8. Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 2007; 16: 1894–7. · DOI
  9. Mulder I, Hoogenveen RT, van Genugten ML, et al. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol 2002; 14: 1343–53. · DOI
  10. Lin Y, Tamakoshi A, Kawamura T, et al. A prospective cohort study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control 2002; 13: 249–54. · DOI
  11. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156: 2255–60. · DOI
  12. Boyle P, Maisonneuve P, Bueno de Mesquita B, et al. Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC. Int J Cancer 1996; 67: 63–71. · DOI
  13. Hruban RH, van Mansfeld ADM, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545–54.
  14. Westra WH, Slebos RJC, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from ex-smokers: evidence that K-ras mutations are an early an irreversible event in the development of adenocarcinoma of the lung. Cancer 1993; 72: 1–7. · DOI · Paper page
  15. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991; 83: 1024–7. · DOI
  16. Westra WH, Offerhaus GJ, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993; 17: 213–20. · DOI
  17. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712–7. · DOI
  18. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92: 1525–30. · DOI
  19. Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008; 122: 155–64. · DOI
  20. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435–51. · DOI
  21. Ahrendt SA, Chow JT, Yang SC, et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 2000; 60: 3155–9.
  22. Shimmyo T, Okada A, Hashimoto T, et al. Etiologic value of p53 mutation spectra and differences with histology in lung cancers. Cancer Sci 2008; 99: 287–95. · DOI
  23. Cox LA, Jr., Sanders E. Estimating preventable fractions of disease caused by a specified biological mechanism: PAHs in smoking lung cancers as an example. Risk Anal 2006; 26: 881–92. · DOI
  24. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801–6.
  25. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503–10. · DOI
  26. Leary RJ, Lin JC, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008; 105: 16224–9. · DOI
  27. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108–13.
  28. Kelsey KT, Hirao T, Hirao S, et al. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int J Cancer 2005; 117: 370–5. · DOI
  29. Ronchetti D, Neglia CB, Cesana BM, et al. Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 303–6. · DOI
  30. Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH. The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 2006; 37: 139–45. · DOI
  31. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 2007; 34: 55–62. · DOI
  32. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 2002; 128: 525–32. · DOI
  33. Crous-Bou M, Porta M, Lopez T, et al. Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer. Pancreas 2007; 35: 135–41. · DOI
  34. Berger DH, Chang H, Wood M, et al. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 1999; 85: 326–32. · DOI
  35. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol 2000; 156: 1641–51. · DOI
  36. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27–32. · DOI
  37. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731–4.
  38. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126–30.
  39. Hruban RH, Iacobuzio-Donahue CA, Wilentz RE, Goggins M, Kern SE. Molecular pathology of pancreatic cancer. Cancer J 2001; 7: 251–8.
  40. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008; 105: 4283–8. · DOI
  41. Wittel UA, Hopt UT, Batra SK. Cigarette smoke-induced pancreatic damage—experimental data. Langenbecks Arch Surg 2008; 393: 581–8. · DOI
  42. Prokopczyk B, Hoffmann D, Bologna M, et al. Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 2002; 15: 677–85. · DOI
  43. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 1994; 84: 1086–93. · DOI
  44. Schofield PE, Hill DJ. How accurate is in-patient smoking status data collected by hospital admissions staff? Aust N Z J Public Health 1999; 23: 654–6. · DOI
  45. Studts JL, Ghate SR, Gill JL, et al. Validity of self-reported smoking status among participants in a lung cancer screening trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1825–8. · DOI

Cited by

Metadata

Authors
Blackford, A., Parmigiani, G., Kensler, T. W., Wolfgang, C., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Eshleman, J. R., Goggins, M., Jaffee, E. M., Iacobuzio-Donahue, C. A., Maitra, A., Klein, A., Cameron, J. L., Olino, K., Schulick, R., Winter, J., Vogelstein, B., Velculescu, V. E., Kinzler, K. W., & Hruban, R. H.
Affiliations
  • 1Oncology, Departments of
  • 6Environmental Health Sciences, and
  • 3Surgery, and
Venue
Cancer Research
Published
2009-04-15
Volume
69
Issue
8
Pages
3681-3688
ISSN
  • 0008-5472
  • 1538-7445
Cited by
113
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review